With USP <800> coming into effect late this year, health care professionals must plan the changes they’ll have to make when handling hazardous drugs. This article from the American Society of Clinical Oncology (ASCO) outlines the new standards and provides advice for implementing them in oncology care settings.
The National Institute for Occupational Safety and Health (NIOSH) publishes a list of Hazardous Drugs in Healthcare Settings, and spironolactone tablets appear on the list as needing special handling. Unlike all other spironolactone dosage forms on the market, the liquid oral suspension CaroSpir does not have a black box warning and does not appear on the NIOSH list.
Read more about USP <800> in this article published in the Journal of Clinical Oncology:
CaroSpir is the first and only FDA-approved oral suspension of the potassium-sparing diuretic spironolactone. To learn more, please visit www.CaroSpir.com to learn more.